Drug Trial Radar · NCT07824869
A Phase II Study of HLX22 in Combination With Trastuzumab and Chemotherapy in HER2-Positive Locally Advanced or Metastatic Breast Cancer Patients
Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Oct 31, 2026
Primary completion
Mar 31, 2028
Study completion Dec 4, 2029
Sponsor
- Lead sponsor
- Shanghai Henlius BiotechIndustry
- Sponsor type
- Industry
- First posted
- Sep 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase II study of HLX22 in combination with trastuzumab and chemotherapy versus placebo in combination with trastuzumab and chemotherapy in locally advanced and/or metastatic HER2-Positive breast cancer previously treated with HER2 ADC. Eligible participants will be treated with the study drug until the loss of clinical benefit, intolerable toxicity, initiation of new anti-tumor therapy, voluntary withdrawal from the study by the patient, loss to follow-up, death, or when the investigator determines that the patient should be withdrawn from the study (whichever occurs first).
Conditions
- HER2 + Breast Cancer
Interventions
HLX22Drug
15 mg/kg, intravenous infusion (IV) on Day 1 (D1) of Q3W
TrastuzumabDrug
Loading dose 8 mg/kg, maintenance dose 6 mg/kg, IV, Q3W, D1.
CapecitabineDrug
1000 mg/m2, oral (po), twice daily (BID), D1-14, Q3W
PaclitaxelDrug
175 mg/m2, D1; or 80-90 mg/m2, D1 D8 D15, Q3W, IV
DocetaxelDrug
75-100 mg/m2, D1, Q3W, IV
EribulinDrug
1.4 mg/m2, D1 and D8, Q3W, IV
VinorelbineDrug
25-30 mg/m2, D1 and D8, Q3W, IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR) assessed by the blinded independent central review (BICR) as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Time frame: Up to 2 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.